Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Operating Margin
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
|
24.2B CNY |
10%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
699.5B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
368.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.7B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.6B GBP |
23%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.3B CHF |
32%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
206.3B USD |
36%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
11%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
119.8B EUR |
21%
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's most recent financial statements, the company has Operating Margin of 9.9%.
You don't have any saved screeners yet